0001213900-21-043010 | 10-Q | XBRL Viewer | Health Sciences Acquisitions Corp 2

Private Placement (Details) $ in Millions	6 Months Ended
Jun. 30, 2021 USD ($) shares
Private Placement (Details) [Line Items]
Purchase price	$ 4.5
Private placement warrants, shares (in Shares) \| shares	1,500,000
Aggregate Price Paid	$ 1.5
Aggregate amount of private placement	6.0
generating gross proceeds	$ 6.0

Basic of Presentation and Summary of Significant Account Policies (Details) - Schedule of basic and diluted net income (loss) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2021
Denominator:
Weighted average shares outstanding of Public Shares, basic and diluted (in Shares)		16,000,000	16,000,000
Numerator:
Less: Net income attributable to Public Shares (in Shares)		(3,989)	(7,935)
Net loss attributable to Founder Shares	$ (15,215)	$ (96,318)	$ (208,266)
Denominator:
Weighted average shares outstanding of Founder Shares, basic and diluted (in Shares)	3,478,261	4,450,000	4,450,000

Initial Public Offering (Details) $ in Millions	Aug. 06, 2020 USD ($)
Initial Public Offering (Details) [Line Items]
Deferred underwriting commissions	$ 5.6

Print Document View Excel Document
Notes Details Basic of Presentation and Summary of Significant Account Policies (Details) - Schedule of basic and diluted net income (loss) Initial Public Offering (Details) Private Placement (Details) Uncategorized Uncategorized Items - f10q0621_health_htm.xml All Reports

Label	Element	Value
NetGainFromInvestmentsHeldInTrustAccount	hsaq_NetGainFromInvestmentsHeldInTrustAccount	$ 3,989
NetGainFromInvestmentsHeldInTrustAccount	hsaq_NetGainFromInvestmentsHeldInTrustAccount	7,935
NetGainFromInvestmentsHeldInTrustAccount	hsaq_NetGainFromInvestmentsHeldInTrustAccount
SubjectToForfeitureShares	hsaq_SubjectToForfeitureShares	521,739
IssuanceOfPublicSharesUnderOverallotment	hsaq_IssuanceOfPublicSharesUnderOverallotment	2,086,956
AggregatePurchasePrice	hsaq_AggregatePurchasePrice	$ 25,000,000
OrdinarySharesSubjectToPossibleRedemption	hsaq_OrdinarySharesSubjectToPossibleRedemption	15,123,645
OrdinarySharesSubjectToPossibleRedemption	hsaq_OrdinarySharesSubjectToPossibleRedemption	15,143,678
UnderwritingAgreementDescription	hsaq_UnderwritingAgreementDescription	The Company granted the underwriters a 45-day option from the date of this prospectus to purchase up to 2,086,956 additional Ordinary Shares at the Initial Public Offering price less the underwriting discounts and commissions.
WeightedAverageShareOutstandingOfFounderSharesBasicAndDilutedinShares	hsaq_WeightedAverageShareOutstandingOfFounderSharesBasicAndDilutedinShares	4,450,000
WeightedAverageShareOutstandingOfFounderSharesBasicAndDilutedinShares	hsaq_WeightedAverageShareOutstandingOfFounderSharesBasicAndDilutedinShares	4,450,000
WeightedAverageShareOutstandingOfFounderSharesBasicAndDilutedinShares	hsaq_WeightedAverageShareOutstandingOfFounderSharesBasicAndDilutedinShares	3,478,261
StockholdersEquityDescription	hsaq_StockholdersEquityDescription	the Company effected a share dividend of 0.113043478 ordinary shares for each outstanding share (an aggregate of 406,250 ordinary shares), resulting in an aggregate of 4,000,000 ordinary shares outstanding. All ordinary shares and associated amounts have been retroactively restated to reflect the share dividend. Of the 4,000,000 ordinary shares outstanding, up to 521,739 of these ordinary shares was subject to forfeiture by the Sponsor (or its permitted transferees) on a pro rata basis depending on the extent to which the underwriters’ over-allotment option was exercised.
SharesSubjectToPossibleRedemptioninShare	hsaq_SharesSubjectToPossibleRedemptioninShare	10,800
SharesSubjectToPossibleRedemptioninShare	hsaq_SharesSubjectToPossibleRedemptioninShare	9,233
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption	$ 1
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption	107,999
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption	108,000
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption	1
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption	92,329
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption	92,330
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption
ShareSubjectToPossibleRedemption	hsaq_ShareSubjectToPossibleRedemption
BorrowedAmount	hsaq_BorrowedAmount	300,000
AccruedExpensesRelatedParty	hsaq_AccruedExpensesRelatedParty	90,000
AccruedExpensesRelatedParty	hsaq_AccruedExpensesRelatedParty	$ 30,000
SharesSubjectToPossibleRedemption	hsaq_SharesSubjectToPossibleRedemption	15,123,645
SharesSubjectToPossibleRedemption	hsaq_SharesSubjectToPossibleRedemption	15,143,678
WorkingCapitalAmount	hsaq_WorkingCapitalAmount	$ 1,900,000
DeferredUnderwritingCommission	hsaq_DeferredUnderwritingCommission	5,600,000
DeferredUnderwritingCommission	hsaq_DeferredUnderwritingCommission	5,600,000
IssuanceOfOrdinarySharesToSponsor	hsaq_IssuanceOfOrdinarySharesToSponsor	400
IssuanceOfOrdinarySharesToSponsor	hsaq_IssuanceOfOrdinarySharesToSponsor	28,350
IssuanceOfOrdinarySharesToSponsor	hsaq_IssuanceOfOrdinarySharesToSponsor	28,750
IssuanceOfOrdinarySharesToSponsor	hsaq_IssuanceOfOrdinarySharesToSponsor
NetIncomeAttributableToPublicShares	hsaq_NetIncomeAttributableToPublicShares	3,989
NetIncomeAttributableToPublicShares	hsaq_NetIncomeAttributableToPublicShares	7,935
NetIncomeAttributableToPublicShares	hsaq_NetIncomeAttributableToPublicShares
ProceedFromIssuanceInitialPublicOffering	hsaq_ProceedFromIssuanceInitialPublicOffering	521,739
PublicPerSharePrice	hsaq_PublicPerSharePrice	10.00
ShareOutstanding	hsaq_ShareOutstanding	406,250
IssuanceOfOrdinarySharesToSponsorinShares	hsaq_IssuanceOfOrdinarySharesToSponsorinShares	4,000,000
IncurredExpenses	hsaq_IncurredExpenses	$ 30,000
IncurredExpenses	hsaq_IncurredExpenses	60,000
ChangeInValueOfOrdinarySharesSubjectToPossibleRedemption	hsaq_ChangeInValueOfOrdinarySharesSubjectToPossibleRedemption	(200,330)
DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering	hsaq_DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering	5,600,000
DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering	hsaq_DeferredUnderwritingCommissionsInConnectionWithTheInitialPublicOffering	5,600,000
AccruedExpensesRelatedPartyOutstanding	hsaq_AccruedExpensesRelatedPartyOutstanding	90,000
AccruedExpensesRelatedPartyOutstanding	hsaq_AccruedExpensesRelatedPartyOutstanding	30,000
LoanAmount	hsaq_LoanAmount	$ 300,000
WarrantsDescription	hsaq_WarrantsDescription	Each warrant is exercisable to purchase one of ordinary shares at an exercise price of $11.50 per full share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.
DescriptionOfPrivatePlacementWarrant	hsaq_DescriptionOfPrivatePlacementWarrant	Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (“Private Placement”) of 450,000 ordinary shares (the “Private Placement Shares”), at a price of $10.00 per Private Placement Share to the Sponsor, (for a total purchase price of $4.5 million), and (ii) 1,500,000 warrants (“Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant (for a total purchase price of $1.5 million), generating gross proceeds to the Company of $6.0 million (Note 4).
AggregatePurchaseToOrdinaryShares	hsaq_AggregatePurchaseToOrdinaryShares	2,500,000